Literature DB >> 10195234

Interferon downregulates CXCR4 (fusin) gene expression in peripheral blood mononuclear cells.

Y Shirazi1, P M Pitha.   

Abstract

OBJECTIVE: Cytokines modulate human immunodeficiency virus type 1 (HIV-1) replication at multiple stages of its life cycle. We examined the effects of several HIV-1-stimulatory and HIV-1-inhibitory cytokines on CXCR4 (fusin) gene expression in lymphoid cells. STUDY DESIGN/
METHODS: Peripheral blood mononuclear cells (PBMCs) were treated with various cytokines, and CXCR4 gene expression was assessed by Northern blot analysis. Cell-cell fusion was assessed using HeLa-MAGI cells expressing T-cell-tropic HIV-1 (i.e., LAV strain) envelope glycoproteins and U937 cells expressing HIV-1 tat.
RESULTS: Although treatment of PBMCs with interferon-alpha (IFN-alpha) and IFN-gamma led to a significant repression of CXCR4 gene expression, interleukin-1 beta (IL-1 beta), IL-6, and tumor necrosis factor-alpha (TNF-alpha) had no significant effect on CXCR4 gene expression in PBMCs. IFN-alpha and IFN-gamma also inhibited CXCR4 gene expression in the promyelocytic cell line U937, and this inhibition led to a decrease in cell-cell fusion between U937 cells and HeLa-MAGI cells. In U937 cells, TNF-alpha and phorbol myristate acetate (PMA) stimulated CXCR4 gene transcription; this effect was reversed with prior treatment of cells with IFN-gamma.
CONCLUSIONS: IFN-alpha and IFN-gamma effectively downmodulate fusin gene expression in lymphoid cells, indicating that IFNs modulate HIV-1 replication at postentry levels as well as at the level of HIV-1 entry.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10195234

Source DB:  PubMed          Journal:  J Hum Virol        ISSN: 1090-9508


  11 in total

1.  A point of view: HIV-1/AIDS is an allergy but CpG ODN treatments may inhibit virus replication and reactivate the adaptive immunity--hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2005-01       Impact factor: 2.332

2.  Alpha interferon enhances TRIM5alpha-mediated antiviral activities in human and rhesus monkey cells.

Authors:  Ryuta Sakuma; Amber A Mael; Yasuhiro Ikeda
Journal:  J Virol       Date:  2007-07-03       Impact factor: 5.103

3.  Characterization of the alpha interferon-induced postentry block to HIV-1 infection in primary human macrophages and T cells.

Authors:  Caroline Goujon; Michael H Malim
Journal:  J Virol       Date:  2010-07-07       Impact factor: 5.103

4.  Tissue microenvironment modulates CXCR4 expression and tumor metastasis in neuroblastoma.

Authors:  Libo Zhang; Herman Yeger; Bikul Das; Meredith S Irwin; Sylvain Baruchel
Journal:  Neoplasia       Date:  2007-01       Impact factor: 5.715

5.  Evidence for a different susceptibility of primate lentiviruses to type I interferons.

Authors:  Stéphanie Cordeil; Xuan-Nhi Nguyen; Gregory Berger; Stéphanie Durand; Michelle Ainouze; Andrea Cimarelli
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

Review 6.  Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors.

Authors:  Hyunsuk Shim; Shinya Oishi; Nobutaka Fujii
Journal:  Semin Cancer Biol       Date:  2008-11-25       Impact factor: 15.707

7.  Effect of interferon-β1b on CXCR4-dependent chemotaxis in T cells from multiple sclerosis patients.

Authors:  T Wostradowski; V Gudi; R Pul; S Gingele; J A Lindquist; M Stangel; S Lindquist
Journal:  Clin Exp Immunol       Date:  2015-08-31       Impact factor: 4.330

8.  A variant macaque-tropic human immunodeficiency virus type 1 is resistant to alpha interferon-induced restriction in pig-tailed macaque CD4+ T cells.

Authors:  Rajesh Thippeshappa; Hongmei Ruan; Weiming Wang; Paul Zhou; Jason T Kimata
Journal:  J Virol       Date:  2013-04-03       Impact factor: 5.103

9.  Anti-human immunodeficiency virus activity of tau interferon in human macrophages: involvement of cellular factors and beta-chemokines.

Authors:  Christine Rogez; Marc Martin; Nathalie Dereuddre-Bosquet; Jacques Martal; Dominique Dormont; Pascal Clayette
Journal:  J Virol       Date:  2003-12       Impact factor: 5.103

Review 10.  Interferon-α Subtypes As an Adjunct Therapeutic Approach for Human Immunodeficiency Virus Functional Cure.

Authors:  Jeffy George; Joseph J Mattapallil
Journal:  Front Immunol       Date:  2018-02-22       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.